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Survival for mesothelioma has been shown to be poor, with marginal improvement over time. Recent advances in the
understanding of pathophysiology and treatment of mesothelioma may impact therapy to improve survival that may
not be evident from available clinical trials that are often small and not randomized. Therapies may affect survival
differently based onmesothelioma location (pleural vs peritoneal). Data are conflicting regarding the effect of asbestos
exposure on mesothelioma location. OBJECTIVES:We examined survival in a large cohort of mesothelioma subjects
analyzed by tumor location and presence andmode of asbestos exposure.METHODS:Datawere analyzed fromcases
(n = 380) diagnosed with mesothelioma from 1992 to 2012. Cases were either drawn from treatment referrals,
independent medical evaluation for medical legal purposes, or volunteers who were diagnosed with mesothelioma.
Subjects completed an occupational medical questionnaire, personal interview with the examining physician, and
physician review of the medical record. RESULTS: This study reports better survival for mesothelioma than historical
reports. Survival for peritoneal mesotheliomawas longer than that for pleural mesothelioma (hazard ratio = 0.36, 95%
confidence interval=0.24-0.54,Pb .001) after adjusting for gender and age at diagnosis. Non-occupational caseswere
more likely to be 1) diagnosedwith peritonealmesothelioma, 2) female, 3) exposed, and 4) diagnosed at a younger age
and to have a 5) shorter latency compared to occupational cases (P b .001). CONCLUSION: Peritoneal mesothelioma
was more likely associated with non-occupational exposure, thus emphasizing the importance of exposure history in
enhancing early diagnosis and treatment impact.
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Asbestos exposure has been recognized as a significant risk factor in
the development of mesothelioma. A history of asbestos exposure can
be found in N80% of mesothelioma cases [1]. Exposure can occur in
both an occupational and a non-occupational setting, such as through
contact with occupationally contaminated individuals and/or their
belongings, exposure to products in the environment, such as floor or
ceiling tiles, insulation, sheet rock, cement, brake dust or through air
currents, such as from nearby factories [2–4]. Individuals exposed in
the non-occupational setting can have similar asbestos fiber lung
burden [5] to those exposed in the occupational setting, presenting
a significant mesothelioma risk [6–8]. Mesothelioma can arise in
various locations—most commonly the pleura and the peritoneum.Early reports suggest that individuals with the heaviest exposure more
often developed peritoneal mesothelioma [9–11]. Results of more
recent reports are mixed [12,13].
36 Malignant Mesothelioma Survival Faig et al. Translational Oncology Vol. 8, No. 1, 2015Recent advances in the understanding of mesothelioma pathophysi-
ology may impact therapy and survival [14,15]. Despite these advances,
reported survival is poor according to the SEER database and improving
only slowly over time [16]. Factors reported to be important in
mesothelioma development are age at first exposure, latency, a personal
and family history of cancers [17], and genetic predisposition [14,18–20].
Recent significant innovations have affected treatment of mesothelioma,
especially peritoneal mesothelioma where hyperthermic intraperitoneal
chemotherapy (HIPEC) and cytoreductive surgery have become standard
of care [21–26]. HIPEC appears to increase survival but can typically be
used to treat only peritoneal mesothelioma. This produces an increased
survival effect that could be misinterpreted as resulting from non-
occupational exposures that are more likely to produce peritoneal tumors.
If exposure type (occupational vs non-occupational) impacts location of
the tumor, then these new treatmentsmay appear to impact survival based
on type of exposure.
Clinical observation has led to a hypothesis that peritoneal
mesothelioma patients live longer than pleural patients and individuals
exposed in a non-occupational setting also appear to live longer than those
exposed in an occupational setting. We set out to test these hypotheses
and to determine current mesothelioma survival.Su
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Figure 1. Mesothelioma survival by location. Kaplan-Meier curve
representing survival in months from diagnosis of peritoneal versus
pleural mesothelioma cases. There was a significant difference in
survival betweengroups,withperitonealmesotheliomapatientshaving
amore favorable survival outcome compared to pleural cases (log-rank
P b .001). Peritoneal mesothelioma survival and pleural mesothelioma
survival are shown as solid and dashed lines, respectively.Material and Methods
Study Population and Data Acquisition
Study subjects (n = 380) were obtained from several sources,
including treatment referrals for peritoneal mesothelioma surgery (n =
21), independent medical evaluations for medical legal purposes (n =
316), and volunteers diagnosed with mesothelioma (n = 43). All
study participants gave informed consent for their participation, and
the protocol was approved by the Institutional Review Boards at Saint
Louis University and Wake Forest School of Medicine.
Study entry criteria included a completed occupational medical
questionnaire and either a death certificate (n = 2) or pathology
report, including immunohistochemical staining documenting the
presence and location of mesothelioma from a CLIA certified hospital
laboratory within the United States or Canada (n = 377). One patient
was a volunteer from a mesothelioma support group and the diagnosis
of mesothelioma was by self report. In most cases, subjects also
underwent a full physical examination (n = 301), personal interview
with the examining physician or study coordinator to clarify
questionnaire responses (n = 380), and physician review of the full
medical record (n = 301). Legal cases frequently had independent
pathologic review in addition to the clinical pathologic diagnostic
workup noted above. Demographic data, such as gender, age, age at
first exposure to asbestos, occupational history, and personal and
family health history, were collected and archived from the
questionnaire/interview. For respondents that reported an occupa-
tional exposure, occupations were categorized into groups based on
the Rice et al. classification [27]. Since there are no large randomized
controlled trials comparing the various mesothelioma therapies
[systemic chemotherapy, extrapleural pneumonectomy (EPP), pleur-
ectomy, radiation, cytoreductive surgery, and/or HIPEC], treatment
modality was not a variable that was analyzed in this study.
Data and Statistical Analysis
Survival rate was determined for both peritoneal versus pleural and
occupationally versus non-occupationally exposed mesothelioma sub-
jects using the Kaplan-Meiermethod and the log-rank test.MultivariateCox proportional hazards regression models were used to determine
predictors of survival. Statistical significance was defined as a P value
b .05. All analyses were performed using SAS 9.2 (Cary, NC). Survival
in months was calculated from the date of mesothelioma diagnosis,
taken from the biopsy pathology report, to the date of death. The closing
date was set at 1 March 2012.
Demographic variables (ages at first exposure and diagnosis,
gender, latency, personal and family history of malignancy) were
compared for both peritoneal versus pleural and occupationally versus
non-occupationally exposed mesothelioma subjects. Frequencies and
proportions were calculated for categorical data. Significance of
differences between two groups was determined by t test or chi square.
Results
Survival
Peritoneal mesothelioma had significantly better survival (hazard
ratio = 0.36, 95% confidence interval = 0.24-0.54, P b .001)
compared to pleural mesothelioma, after adjusting for age at diagnosis
and gender (Figure 1). The median survival for pleural and peritoneal
mesothelioma cases was 18.4 (range 0.26-142.69) and 75.7 (0.79-
326.30) months, respectively (Table 1). The percent survival at 1, 3,
5, and 10 years for pleural mesothelioma cases was 73.1%, 22.9%,
12.0%, and 4.7%, respectively, whereby the percent survival at 1, 3,
5, and 10 years for peritoneal mesothelioma cases was 91.6%, 73.8%,
65.3% and 39.4%, respectively. Subjects exposed in the non-
occupational setting were more likely to develop the longer surviving
peritoneal rather than pleural mesothelioma. Despite a large difference in
median survival between occupational and non-occupational cases, there
was no significant difference after adjusting for age at diagnosis and gender
(Table 1; P = .86). The number of subjects surviving at the end of the
study (1 March 2012) was 92 (48/16% pleural and 44/57% peritoneal).
Demographic and Occupational Data
Of the 380 mesothelioma subjects that met inclusion criteria, 303
were pleural and 77 peritoneal cases (Table 1). Most (64%) of the
Table 1. Survival and Demographic Data
Age at First Exposure,
Mean + SD
Age at Diagnosis,
Mean ± SD
Latency (Years),
Mean ± SD
Gender (%,
Male/Female)
Median Survival in
Months (Range)
Past Personal or Family
History of Cancer, n (%)
Location Pleural, n = 303 17.4 ± 7.8 66.7 ± 11.9 49.8 ± 11.3 81/19 18.4 (0.26-142.69) 220 (72.6%)
Peritoneal, n = 77 12.1 ± 0.2 50.7 ± 15.1 9.1 ± 12.7 39/61 75.7 (0.79-326.3) 55 (71.4%)
Exposure type Occupational, n = 284 18.7 ± 6.4 67.3 ± 11.2 49.2 ± 10.9 93/7 19.71 (0.26-144.66) 210 (73.9%)
Non-occupational, n = 96 9.3 ± 10.2 51.9 ± 15.6 43.2 ± 15.1 12.5/87.5 53.74 (2.69-326.3) 65 (67.7%)
Subjects who were occupationally exposed were initially exposed to asbestos and diagnosed with mesothelioma at an older age (P b .001) and also had a longer latency (P b .001) than subjects who were
exposed in a non-occupational setting.
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(49 HIPEC, 22 systemic chemotherapy, 6 unknown). Of the patients
exposed to asbestos in an occupational setting, 257 (90.5%) developed
pleural and 27 (9.5%) developed peritoneal mesothelioma. Of the
non-occupational cases, 46 (47.9%) developed pleural mesothelioma
and 50 (52.1%) developed peritoneal mesothelioma (Figure 2).
Non-occupational cases were exposed to asbestos at a younger age, were
diagnosed at an earlier age, and had a shorter latency compared to
occupational cases (Table 1). The majority of occupationally exposed
mesothelioma cases weremen, whereas themajority of the non-occupational
cases were women. Laborer/factory worker was the most common
occupation for pleural mesothelioma. Construction worker was the most
common occupation for peritoneal mesothelioma cases (Table 2).
Discussion
This study shows that survival for peritoneal mesothelioma patients
was significantly better than pleural mesothelioma patients, which
may be reflective of differences in the natural history of these two
forms of mesothelioma, effect of newer therapies, or both. The
prognosis for peritoneal mesothelioma has improved significantly
in recent years due to therapeutic advancements, especially with
HIPEC coupled with cytoreductive surgery [28]. Of the reports cited
[21–26], the median survival values for peritoneal mesothelioma
patients receiving cytoreductive surgery plus HIPEC falls within the
range of 34 to 92 months. A more recent review of the literature [29]
lists a range of 53 to 92 months for median survival, which isFigure 2. Anatomic locationofmesotheliomawith regard to exposure
type.A total of 380patientswere enrolled in the study. Therewere284
patients exposed to asbestos in an occupational setting: 257 (90.5%)
developed pleural mesothelioma and 27 (9.5%) developed peritoneal
mesothelioma. There were 96 patients exposed to asbestos in the
non-occupational setting: 46 (47.9%) developed pleural mesothelio-
ma and 50 (52.1%) developed peritoneal mesothelioma.suggestive of survival improving over time. Heated intraoperative
chemotherapy (HIOC) has also been used in conjunction with EPP
with and without adjuvant radiation therapy [30–32]. It has been
shown to be safe [31,32] and effective [30]. Sugarbaker and coworkers
showed that addition of HIOC to EPP improved median survival from
12.8 to 27.1 months. There was, however, no significant difference
between EPP +HIOC and EPP + radiation therapy [30].While HIOC
+ EPP appears to double mean survival compared with EPP alone, the
mean survival for pleural mesothelioma treated withHIOC + EPP is far
less than that reported for peritoneal mesothelioma treated withHIPEC
+ cytoreductive surgery, which suggests a difference in the natural
history of pleural versus peritoneal mesothelioma regardless of
treatment. Because these studies were not randomized, they must,
however, be interpreted with caution.
The reported range for median survival for pleural mesothelioma in
a 2009 review, regardless of stage, was between 9 and 17 months [33].
Other more recent reviews show no improvement in survival
compared to this review [34,35]. Our data are consistent with, but
at the upper end of, median survival values reported by other studies
for both peritoneal and pleural cases, suggesting that newer therapies
do improve survival. A case series of 238 pleural and peritoneal
mesotheliomas suggests that survival rates outside of therapy trials
reported as recently as 2011 were still low, with a reported overall
survival of 8.8 months with mean survival increasing to 11.3 months
in patients receiving therapy versus 6.4 months in those that remained
untreated [36]. This case series was dominated by pleural cases
(94.4%) underscoring the difference in natural histories of pleural and
peritoneal mesotheliomas, but the mean survival is still quite lowTable 2. Exposure History
Occupation Pleural, n (%) Peritoneal, n (%)
Occupational exposure: ship related
Military 36 (14.0)
Occupational exposure: mining and milling
Mine Worker 3 (1.2)
Occupational exposure: end users/maintenance/asbestos as a contaminant
Factory laborer 52 (20.3) 6 (22.2)
Construction 44 (17.1) 9 (33.4)
Maintenance/repair/mechanic 28 (10.9) 5 (18.5)
Pipe fitter 14 (5.4) 1 (3.7)
Shipping/receiving 14 (5.4)
Sheet metal worker 11 (4.3)
Machinist 11 (4.3) 1 (3.7)
Farming 9 (3.5) 2 (7.4)
Boiler worker 7 (2.7)
Chemical worker 3 (1.2) 1 (3.7)
Railroad worker 2 (0.8)
Other occupational exposure
Non-industrial/non-labor 11 (4.3) 1 (3.7)
Office/clerical 5 (1.9)
Other 7 (2.7) 1 (3.7)
Occupations of the 284 occupationally exposed cases categorized according to Rice [27].
38 Malignant Mesothelioma Survival Faig et al. Translational Oncology Vol. 8, No. 1, 2015compared with our reported median survival of 18.4 (range
0.26-142.69), further illustrating improvements in survival over
time. Unfortunately, many patients with both pleural and peritoneal
mesothelioma are often diagnosed at a late stage. Although the treatment
ofmesothelioma is evolving, these patientsmay benefit less from therapies
because of advanced disease, highlighting the role of asbestos exposure
history in early diagnosis.
Exposure type (occupational or non-occupational) did affect survival
but only because subjects exposed in the non-occupational setting were
more likely to develop the longer surviving peritoneal rather than
pleural mesothelioma. Subjects exposed in the occupational setting had
a median survival of 19.71 (0.26-144.66) months, whereby those
exposed in the non-occupational setting had a median survival of 53.74
(2.69-326.30) months. When survival was adjusted for gender and age
at diagnosis however, exposure type did not significantly affect survival.
The non-occupational group had a significantly greater proportion of
females and a younger age at first exposure and diagnosis. Report of
these data is important because non-occupational subjects are more
likely to be under-recognized than those with occupational exposure
because of recall and gender bias. However, they are also more likely to
develop peritoneal mesothelioma, which is more amenable to the newer
therapies that are associated with longer survival.
This study has several limitations. The authors recognize that there
is potential for the introduction of confounding variables resulting
from a selection bias in the subject pool as a function of a clinician's
interest in medico-legal issues or in mesothelioma treatment, per se.
The overall n of 380 represents a significant number of subjects,
considering that only 3000 new diagnoses are made each year,
nationwide. The authors felt that the large number of subjects and
histopathologic or death certificate confirmation of cases was more
than sufficient to wash out any effect of variance in this study based
on referral bias.
Asbestos exposure was based on patient report that can be flawed
by memory.
Furthermore, no attempt was made to quantify dose or fiber type
of asbestos given the reliance on patient report. While certain
occupational categories would suggest a preponderance of amphibole
exposure and many occupational exposures are mixed as to fiber
type, all the fiber types cause pleural and peritoneal mesotheliomas,
and therefore knowing the fiber type in each case is not necessary,
particularly in a study like this one [37].
Additionally, most, if not all, subjects were involved in litigation,
whichmay bias the reporting of extent of asbestos exposure. Conversely,
however, it could cause bias based on court required proof of exposure
and pathologic evidence of mesothelioma that is more rigorous than
patient reported medical histories not involved in litigation. On the
basis of the recommendation of the American Thoracic Society, subjects
not involved in litigation were told at the time of evaluation that they
had cause for legal action [38].
Tumor misclassification especially in peritoneal cases where
ovarian tumors can be misdiagnosed as mesothelioma is unlikely in
this study. Pathology reports including immunohistochemical
staining were available on all peritoneal cases. Furthermore, most,
if not all, had expert second and third consultative pathology reports
related to litigation and treatment at a tertiary care center.
Another limitation of this study is that past personal and family
history of cancer was from patient report, with confirmation, when
available, from the medical record. While this is an imperfect approach
in documenting this important phenotypic data, the presence of acancer history is consistent with and further enhances the validity of the
mesothelioma diagnosis [17,39–41].
Emerging data regarding pathophysiology of mesothelioma suggest that
non-occupational and occupational asbestos exposure are non-differentiating
variables with regard to causality [5,42,43]. These studies demonstrate
that asbestos exposure may be as high in the non-occupational as the
occupational setting. Asbestos exposure dose is equal to fiber density
times duration of exposure. While fiber dose may be lower in the
non-occupational settings, duration of exposure can be much longer in
the non-occupational compared with the occupational setting.
Occupationally exposed individuals are generally limited to about
2000 exposure hours per year, whereas non-occupational exposure is
unlimited, because the asbestos fibers permeate their environment.
Therefore, cumulative exposure may be comparable between occupa-
tional and non-occupational cases [43]. As such, exposure intensity is
just one factor in determining mesothelioma development.
Recent evidence suggests that genetic susceptibility is another factor
for mesothelioma development. Genetic predisposition is complex in
that genes can affect 1) tumorogenesis, [14,18,44] 2) the ability to
spread and metastasize, 3) immune surveillance that aborts tumor
growth and development, and 4) response to chemotherapy.
This dynamic interaction between genes and asbestos exposure suggests
that asbestos dose may play a less significant role in mesothelioma
development than previously thought and that genetic predisposition
may play a larger causative role. Further research is required to ferret out
the differential impact of genetics and asbestos exposure.
Conclusion
Survival is improving for peritoneal and, to a lesser extent, pleural
mesothelioma and appears to be longer than reported in historical
accounts. This study emphasizes the increasing difference in survival of
peritoneal versus pleural cases and the importance of obtaining a thorough
occupational and non-occupational exposure history when evaluating a
patient with signs or symptoms of a thoracic or abdominal malignancy.
Finally, results of this study suggest that further investigation into
the role of other factors, which were beyond the scope of this study,
would be of significant value. The authors suggest that future research
in this area examines the role that such independent variables as
1) genetic predisposition, 2) gene environment interactions, and
3) various treatment modalities, such as intraperitoneal chemotherapy
versus systemic chemotherapy, may play in patient longevity.
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